What is Bit Bio?
Bit Bio operates at the forefront of synthetic biology, leveraging its patented opti-ox technology to create precisely engineered human cell types. This capability is crucial for advancing drug discovery pipelines, enabling more accurate preclinical testing, and paving the way for novel cell-based therapies. The company's platform allows for the scalable and reproducible generation of specific cell populations, addressing a critical need in the life sciences sector for high-quality, consistent cellular materials for research and therapeutic development.
How much funding has Bit Bio raised?
Bit Bio has raised a total of $255M across 6 funding rounds:
Angel/Seed
$471K
Series A
$41.5M
Series B
$103M
Other Financing Round
$30M
Private Equity
$30M
Series C
$50M
Angel/Seed (2017): $471K with participation from Jonathan Milner
Series A (2020): $41.5M led by Arch Venture Partners, Foresite Capital, Blueyard Capital, and Richard Klausner
Series B (2021): $103M supported by Arch Ventures, Charles River Laboratories, Foresite Capital, and National Resilience
Other Financing Round (2024): $30M featuring ARCH VENTURE PARTNERS, Tencent, and M&G Investments
Private Equity (2024): $30M backed by BlueYard Capital, M&G, Puhua Capital, and ARCH VENTURE PARTNERS
Series C (2026): $50M with participation from M&G
Key Investors in Bit Bio
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
BlueYard Capital
BlueYard Capital is a venture capital firm that invests in innovative technologies across various sectors, including computation, engineering, biology, and cryptocurrency. The firm focuses on supporting founders who are building solutions that contribute to a better future while addressing significant global challenges.
What's next for Bit Bio?
With substantial enterprise-level backing and a recent strategic investment, Bit Bio is poised for accelerated growth and innovation. The company's trajectory suggests a focus on scaling its manufacturing capabilities, expanding its product portfolio of differentiated cell types, and forging strategic partnerships within the pharmaceutical and biotechnology industries. Further investment will likely fuel advancements in clinical translation for its cell therapy applications and broaden the reach of its research tools, solidifying its position as a key player in the synthetic biology landscape.
See full Bit Bio company page
